CinDome Pharma Announces First Patient Dosed in the envisionGI Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis
CinDome announces that the first participant has been dosed in the envisionGI Phase 2 clinical trial of deudomperidone (CIN-102) in adults with idiopathic gastroparesis.
CinDome Pharma Announces $40 Million Series B Extension
CinDome Pharma Announces $40 Million Series B Extension
CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference
CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference.
